Studies show that kidneys produce 2Ј,3Ј-cAMP, 2Ј,3Ј-cAMP is exported and metabolized to 2Ј-AMP and 3Ј-AMP, 2Ј-AMP and 3Ј-AMP are metabolized to adenosine, 2Ј,3Ј-cAMP inhibits proliferation of preglomerular vascular smooth muscle cells (PGVSMCs) and glomerular mesangial cells (GMCs), and A 2B (not A 1 , A 2A , or A 3 ) adenosine receptors mediate part of the antiproliferative effects of 2Ј,3Ј-cAMP. These findings suggest that extracellular 2Ј,3Ј-cAMP attenuates proliferation of PGVSMCs and GMCs partly via conversion to corresponding AMPs, which are metabolized to adenosine that activates A 2B receptors. This hypothesis predicts that extracellular 2Ј-AMP and 3Ј-AMP should exert A 2B receptormediated antiproliferative effects. Therefore, we examined the antiproliferative effects (cell counts) of 2Ј-AMP and 3Ј-AMP. In PGVSMCs and GMCs, 2Ј-AMP and 3Ј-AMP exerted concentration-dependent antiproliferative effects. 3Ј-AMP was equipotent with and 2Ј-AMP was 3-fold less potent than 5Ј-AMP (prototypical adenosine precursor). In PGVSMCs, the effects of 2Ј-AMP and 3Ј-AMP were mimicked by adenosine, and 8-[4-[((4-cyanophenyl)carbamoylmethyl)oxy]phenyl]-1,3-di(npropyl)xanthine (MRS-1754) (A 2B receptor antagonist) equally blocked the antiproliferative effects of 2Ј-AMP, 3Ј-AMP, and adenosine but less effectively blocked the effects of 2Ј,3Ј-cAMP. Similar results were obtained in GMCs except that MRS-1754 also incompletely blocked the effects of 3Ј-AMP. We conclude that in PGVSMCs, 2Ј-AMP and 3Ј-AMP are antiproliferative, the antiproliferative effects of 2Ј-AMP and 3Ј-AMP are mediated nearly entirely by adenosine/A 2B receptors, and some of the antiproliferative effects of 2Ј,3Ј-cAMP are independent of adenosine/A 2B
Introduction
Studies using high-performance liquid chromatographytandem mass spectrometry demonstrate the production and release into the extracellular compartment of 2Ј,3Ј-cAMP, a positional isomer of 3Ј,5Ј-cAMP, by intact rat kidneys . Moreover, experiments in intact rat kidneys show that extracellular 2Ј,3Ј-cAMP is metabolized to extracellular 2Ј-AMP and 3Ј-AMP and that these AMPs are further metabolized to extracellular adenosine (a mechanism called the extracellular 2Ј,3Ј-cAMP-adenosine pathway) .
More recent studies indicate that extracellular 2Ј,3Ј-cAMP has biological effects on kidney cells . For example, extracellular 2Ј,3Ј-cAMP inhibits the proliferation of preglomerular vascular smooth muscle cells (PGVSMCs) and glomerular mesangial cells (GMCs). Mechanistically, this inhibition is probably in part due to conversion of 2Ј,3Ј-cAMP to adenosine, a conclusion supported by the observations that the antiproliferative effects of 2Ј,3Ј-cAMP are accompanied by the metabolism of 2Ј,3Ј-cAMP to 2Ј-AMP and 3Ј-AMP, which are further metabolized to adenosine , and the antigrowth effects of 2Ј,3Ј-cAMP are attenuated by antagonism of A 2B receptors with 8- [4-[((4-cyanophenyl) . In addition, previous studies demonstrated that adenosine, via A 2B receptors, inhibits growth of vascular smooth muscle cells and GMCs (Dubey et al., 1996b (Dubey et al., , 1998b (Dubey et al., , 2000 (Dubey et al., , 2005 . It seems likely then that extracellular 2Ј,3Ј-cAMP inhibits growth of PGVSMCs and GMCs at least in part via the extracellular 2Ј,3Ј-cAMP-adenosine pathway, which then activates antiproliferative A 2B receptors (solid arrows in Fig. 1 ). However, this hypothesis predicts that extracellular 2Ј-AMP and 3Ј-AMP should also exert antiproliferative effects that are blocked by antagonism of A 2B receptors, and this prediction has yet to be tested. Therefore, a major objective of this study was to further test the hypothesis shown in Fig. 1 (solid arrows) by examining the antiproliferative effects of 2Ј-AMP and 3Ј-AMP in the absence and presence of a selective and potent A 2B receptor antagonist.
Although extracellular 2Ј,3Ј-cAMP probably inhibits growth of PGVSMCs and GMCs in part via the extracellular 2Ј,3Ј-cAMP-adenosine pathway and via A 2B receptors , it is conceivable that extracellular 2Ј,3Ј-cAMP has antiproliferative effects that are not adenosine-mediated. In this regard, it is possible that 2Ј,3Ј-cAMP exerts nonadenosine-mediated antiproliferative actions that are also independent of 2Ј-AMP or 3Ј-AMP (dashed arrows in Fig. 1) ; it is also conceivable that 2Ј,3Ј-cAMP has antiproliferative actions that are due to nonadenosine-mediated effects of 2Ј-AMP or 3Ј-AMP (dotted arrows in Fig. 1 ). Therefore, another goal of the present study was to explore the possibility that extracellular 2Ј,3Ј-cAMP inhibits growth of PGVSMCs and GMCs independently of adenosine.
Materials and Methods
Animals. PGVSMCs and GMCs were harvested from adult male Wistar-Kyoto rats (Taconic Farms, Germantown, NY). The institutional animal care and use committee approved all procedures, and the investigation conforms to the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, 1996) .
Drugs. 2Ј,3Ј-cAMP, 5Ј-AMP, 3Ј-AMP, 2Ј-AMP, and MRS-1754 [selective A 2B receptor antagonist (Jacobson and Knutsen, 2001) ] were obtained from Sigma-Aldrich (St. Louis, MO).
Cell Culture. Rat PGVSMCs and GMCs were harvested and cultured as described by us previously (Dubey et al., 1992; Mokkapatti et al., 1998) . All experiments were performed in cells in third to fifth passage.
Cell Proliferation Studies. Cell proliferation studies were conducted as described previously (Dubey et al., 1996a) . In brief, PGVSMCs and GMCs were plated at an initial density of 5000 cells/culture in Dulbecco's modified Eagle's medium Nutrient Mixture F-12 (DMEM/F12) containing 2.5% fetal calf serum and were allowed to attach and proliferate overnight. The next day, cells were growth-arrested in DMEM/F12 containing 0.25% albumin for 24 h to synchronize cells. Then DMEM/F12 containing 2.5% fetal calf serum (along with the various treatments) was added to stimulate cell proliferation. Treatments were administered daily, and after 4 days the cell number was determined by counting cells with a Coulter counter.
Statistics. Data were analyzed by one-or two-factor analysis of variance, with post hoc comparisons using Fisher's least significant difference test if the main effects of the analysis of variance were significant. The criterion of significance was p Ͻ 0.05. All values in text and figures are means Ϯ S.E.M.
Results
We first investigated the concentration-dependent effects of 2Ј-AMP and 3Ј-AMP on proliferation of PGVSMCs and GMCs. As shown in Fig. 2 , both 2Ј-AMP and 3Ј-AMP significantly, profoundly, and concentration dependently attenuated the proliferation of PGVSMCs ( Fig. 2A) and GMCs (Fig.  2B ). Of importance, 3Ј-AMP was as potent and efficacious in this regard as the prototypical adenosine precursor, 5Ј-AMP. Although 2Ј-AMP was approximately 3-fold less potent than 3Ј-AMP and 5Ј-AMP, nonetheless, 2Ј-AMP was an effective inhibitor of PGVSMC and GMC proliferation (Fig. 2, A and B, respectively). 2Ј-AMP, 3Ј-AMP, and 5Ј-AMP did not affect cell morphology or trypan blue exclusion, indicating that the AMPs did not alter cell viability.
Next, we examined whether the effects of 2Ј-AMP and 3Ј-AMP in PGVSMCs could be accounted for by adenosine acting via A 2B receptors. The ability of 2Ј-AMP (30 M) to inhibit PGVSMC proliferation was abolished by MRS-1754 (100 nM) (Fig. 3A) , and the ability of 3Ј-AMP (30 M) to inhibit PGVSMC proliferation was nearly abolished (Fig.  3B) . In contrast to 2Ј-AMP and 3Ј-AMP, although the antiproliferative effects of 2Ј,3Ј-cAMP (30 M) were reduced by MRS-1754 (100 nM), there remained a considerable antiproliferative effect of 2Ј,3Ј-cAMP even in the presence of MRS-1754 (Fig. 3C ). MRS-1754 (100 nM) inhibited nearly all of the antiproliferative actions of adenosine (Fig. 3D ), indicating Subsequently, we examined whether the effects of 2Ј-AMP and 3Ј-AMP in GMCs could be accounted for by adenosine acting via A 2B receptors. The ability of 2Ј-AMP (30 M) to inhibit GMC proliferation was abolished by MRS-1754 (100 nM) (Fig. 4A) , and the ability of 3Ј-AMP (30 M) to inhibit GMC proliferation was attenuated but clearly present (Fig.  4B) . In contrast to 2Ј-AMP, although the antiproliferative effects of 2Ј,3Ј-cAMP (30 M) were reduced by MRS-1754 (100 nM), there remained a considerable antiproliferative effect of 2Ј,3Ј-cAMP even in the presence of MRS-1754 (Fig.  4C) . As in PGVSMCs, in GMCs, MRS-1754 (100 nM) inhibited nearly all of the antiproliferative actions of adenosine (Fig. 4D) , indicating that the concentration of MRS-1754 was adequate to antagonize the A 2B receptor in GMCs.
The data in Figs. 3 and 4 were used to statistically compare the percent reversal (antagonism) by MRS-1754 of the antiproliferative effects of adenosine, 2Ј,3Ј-cAMP, 2Ј-AMP, and 3Ј-AMP. As shown in Fig. 5 , in PGVSMCs (Fig. 5A ) the antagonism by MRS-1754 of the antiproliferative effects of the purines was 1) nearly complete for adenosine, 2Ј-AMP, and 3Ј-AMP, 2) not statistically significantly different for adenosine versus 2Ј-AMP versus 3Ј-AMP, and 3) statistically significantly less for 2Ј,3Ј-cAMP versus those of the other three purines (adenosine, 2Ј-AMP, and 3Ј-AMP). As shown in Fig. 5B , similar results were obtained in GMCs with the exception that although MRS-1754 antagonized the effects of 3Ј-AMP more so than the effects of 2Ј,3Ј-cAMP, the antagonism by MRS-1754 was greater against adenosine than against 3Ј-AMP.
Discussion
Very little is known about the pharmacology of 2Ј-AMP or 3Ј-AMP. However, the discovery that 2Ј,3Ј-cAMP is endogenously generated and can be metabolized to 2Ј-AMP and 3Ј-AMP Ren et al., 2009 ) provides strong motivation to explore thoroughly the pharmacology and physiology of these neglected AMPs. The existence of 2Ј,3Ј-cyclic nucleotide 3Ј-phosphodiesterase, an enzyme that can metabolize 2Ј,3Ј-cAMP to 2Ј-AMP (Sprinkle, 1989) , along with the important recent discovery by Rao et al. (2010) of six different phosphodiesterases that metabolize 2Ј,3Ј-cAMP to 3Ј-AMP, stimulates additional enthusiasm for investigating the pharmacology and physiology of AMPs generated from 2Ј,3Ј-cAMP.
In the current report, we focused on the pharmacological effects of 2Ј-AMP and 3Ј-AMP on proliferation of PGVSMCs and GMCs. The incentive for these experiments is that previously published data indicated that 2Ј,3Ј-cAMP inhibits PGVSMC and GMC proliferation in part via adenosine A 2B receptors and that the mechanism seems to be 2Ј,3Ј-cAMP 3 2Ј-AMP ϩ 3Ј-AMP 3 adenosine 3 A 2B receptor activation 3 antiproliferative effect. This model predicts that 2Ј-AMP or 3Ј-AMP ought also to inhibit PGVSMC and GMC proliferation and the antiproliferative effects of the AMPs should be at least partially blocked by antagonism of A 2B adenosine receptors. Indeed, the present experiments confirm that both 2Ј-AMP and 3Ј-AMP potently and efficaciously inhibit proliferation of both PGVSMCs and GMCs via, at least in part, A 2B receptors.
Our previous study regarding the antiproliferative effect of 2Ј,3Ј-cAMP demonstrates that a portion of the antiproliferative action of 2Ј,3Ј-cAMP, as assessed by thymidine incorporation, is not reversed by antagonism of A 2B receptors with MRS-1754 . This result suggests that either 2Ј,3Ј-cAMP has nonadenosine-mediated effects or that some of the antiproliferative effects of the adenosine generated from 2Ј,3Ј-cAMP are mediated in part by A 1 , A 2A , or A 3 adenosine receptors. However, the second possibility is ruled out by our findings that the antiproliferative effects of 2Ј,3Ј-cAMP are not affected whatsoever by antagonism of A 1 , A 2A , or A 3 adenosine receptors . In addition, our previous studies showed that the antiproliferative effects of adenosine are accompanied by increases in intracellular levels of 3Ј,5Ј-cAMP (suggestive of A 2B receptor signaling), are inhibited by antisense oligonucleotide-induced down-regulation of A 2B receptors, and are not mimicked by selective A 1 , A 2A , or A 3 receptor agonists (Dubey et al., 1996b (Dubey et al., , 1997 (Dubey et al., , 1998a (Dubey et al., ,b, 2000 (Dubey et al., , 2001 (Dubey et al., , 2005 . Thus, we are left with the possibility that 2Ј,3Ј-cAMP has effects that are independent of adenosine.
The results of the present study confirm, using cell counting (a more reliable index of antiproliferative effects), that although some of the antiproliferative effects of 2Ј,3Ј-cAMP are mediated via adenosine acting on A 2B receptors, indeed a portion of the effects are not mediated by adenosine. In this regard, we observe that concentrations of MRS-1754 that nearly abolish the antiproliferative effects of adenosine are statistically less effective in preventing the effects of 2Ј,3Ј-cAMP. Because the concentration of MRS-1754 used in the present study effectively prevents the antiproliferative actions of adenosine, the lack of full reversal of 2Ј,3Ј-cAMPinduced growth inhibition is not due to inadequate concentrations of MRS-1754. This result is consistent with the fact that the K i of MRS-1754 for A 2B receptors is approximately 2 nM (Jacobson and Knutsen, 2001; Kalla et al., 2009) , and the current study uses a concentration of 100 nM (50-fold greater than the K i ). Thus, the present study confirms that 2Ј,3Ј-cAMP has adenosine-independent actions.
The adenosine-independent actions of 2Ј,3Ј-cAMP could be independent of the antiproliferative effect of its "downstream" AMPs or could be mediated by antiproliferative actions of 2Ј-AMP or 3Ј-AMP that are adenosine-independent. The present study demonstrates that in PGVSMCs, MRS-1754 abolishes the antiproliferative effects of 2Ј-AMP and nearly abolishes the antiproliferative effects of 3Ј-AMP. Of importance, there is no statistically significant difference between adenosine, 2Ј-AMP, and 3Ј-AMP with regard to reversal of their antiproliferative effects by MRS-1754. Thus, in PGVSMCs the evidence supports the conclusion that 2Ј,3Ј-cAMP exerts an adenosine-independent antiproliferative effect that bypasses both 2Ј-AMP and 3Ј-AMP (dashed arrow in Fig. 1 ). On the other hand, in GMCs, although MRS-1754 reverses completely the antiproliferative effects of 2Ј-AMP, MRS-1754 is unable to block the effects of 3Ј-AMP as efficiently as the effects of adenosine or 2Ј-AMP. Moreover, MRS-1754 has even less effect on 2Ј,3Ј-cAMP than on 3Ј-AMP. Thus, in GMCs, the evidence supports the conclusion that 2Ј,3Ј-cAMP exerts an adenosine-independent antiproliferative effect that bypasses both 2Ј-AMP and 3Ј-AMP (dashed arrow in Fig. 1 ) but also exerts an adenosine-independent antiproliferative effect that is due to the nonadenosine-dependent effects of 3Ј-AMP.
The present study does not address the mechanisms of the nonadenosine-mediated antiproliferative component of 2Ј,3Ј-cAMP or 3Ј-AMP. Studies by Azarashvili et al. (2009) demonstrated that in isolated mitochondria 2Ј,3Ј-cAMP promotes the opening of mitochondrial permeability transition pores, and studies by Johnson et al. (1989) in detergent-solubilized and purified tissue preparations showed that 3Ј-AMP is a P site inhibitor of adenylyl cyclase. It is conceivable that these 
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at ASPET Journals on July 10, 2017 jpet.aspetjournals.org reported effects of 2Ј,3Ј-cAMP and 3Ј-AMP are involved in the nonadenosine-mediated antiproliferative actions of these purines. However, in the present study these compounds are applied extracellularly. Although cAMPs are actively pumped out of cells (Barber and Butcher, 1983; Deeley et al., 2006; Li et al., 2007; Cheng et al., 2010) , because both 2Ј,3Ј-cAMP and 3Ј-AMP are very hydrophilic, they are not likely to diffuse across cell membranes into cells. Because the effects on mitochondria and the P site of adenylyl cyclase would require an intracellular action of 2Ј,3Ј-cAMP and 3Ј-AMP, it seems unlikely that these mechanisms are involved. Moreover, whereas activation of A 2B receptors stimulates adenylyl cyclase and inhibits proliferation; in contrast, interaction of 3Ј-AMP with the P site inhibits adenylyl cyclase, an effect not predicted to inhibit proliferation.
As mentioned, our recent report showed that 2Ј,3Ј-cAMP, 2Ј-AMP, and 3Ј-AMP are metabolized to adenosine in PGVSMCs and GMCs , and our previous studies (Dubey et al., 1996b (Dubey et al., , 1998b (Dubey et al., , 2000 (Dubey et al., , 2005 and the current study demonstrate that adenosine inhibits proliferation of vascular smooth muscle cells and GMCs via A 2B receptors. Thus, it is likely that any antiproliferative effects of 2Ј,3Ј-cAMP, 2Ј-AMP, and 3Ј-AMP prevented by MRS-1754 are mediated by adenosine generated from these purines. Although it is logically possible that 2Ј,3Ј-cAMP, 2Ј-AMP, and 3Ј-AMP could be acting in part as direct A 2B receptor agonists, this possibility is extremely unlikely. The pharmacology and structure-activity analysis of a vast number of adenosine analogs support the conclusion that the 2Ј-hydroxy and 3Ј-hydroxy moieties on the ribose ring of adenosine analogs are, with very few exceptions not involving negatively charge substituents, required for activity at adenosine receptors (Jacobson and Knutsen, 2001 ). However, rigorous testing of this hypothesis must await the availability of inhibitors that can block the conversion of 2Ј,3Ј-cAMP, 2Ј-AMP, and 3Ј-AMP to adenosine.
Evidence is rapidly accumulating that renovascular A 2B receptors play an important role in the renal microcirculation. For example, A 2B receptors are strongly expressed in rat preglomerular microvessels (Jackson et al., 2002) , and studies in A 2B receptor knockout mice provide striking evidence that adenosine (Grenz et al., 2007a,b) via activation of renovascular A 2B receptors mediates renal ischemic preconditioning and protects the kidney from ischemia/reperfusion injury. Moreover, renovascular A 2B receptors dampen the hypoxia-induced vascular leak in mouse kidneys , and recent studies using the rat in vitro blood-perfused juxtamedullary nephron technique show that A 2B receptors in the afferent arteriole cause profound vasodilation and counteract A 1 receptor-induced vasoconstriction (Feng and Navar, 2010) . The fact that 2Ј,3Ј-cAMP, 2Ј-AMP, and 3Ј-AMP can be metabolized to adenosine and can thereby activate renovascular A 2B receptors suggests that the 2Ј,3Ј-cAMP-adenosine pathway not only may regulate vascular and glomerular structure via antiproliferative effects but may also participate in renal protection and regulation of renovascular tone.
In summary, the present study shows for the first time that 2Ј-AMP and 3Ј-AMP exert antiproliferative effects in both PGVSMCs and GMCs. In PGVSMCs, these effects are completely mediated by adenosine-A 2B receptor interactions. In GMCs, all of the antiproliferative effects of 2Ј-AMP are due to adenosine; however, in GMCs a small component of the antiproliferative effects of 3Ј-AMP is independent of adenosine. Finally, in both PGVSMCs and GMCs, 2Ј,3Ј-cAMP has antiproliferative effects independent of 2Ј-AMP, 3Ј-AMP, and adenosine. Because mRNA turnover is a major endogenous source of 2Ј,3Ј-cAMP , increased mRNA metabolism stimulated by apoptosis (Del Prete et al., 2002) may inhibit PGVSMC and GMC growth and limit pathological remodeling in renal diseases via production of 2Ј,3Ј-cAMP, 2Ј-AMP, and 3Ј-AMP. Moreover, part of the pharmacology of rapamycin, which stimulates mRNA turnover (Banholzer et al., 1997; Hashemolhosseini et al., 1998; Albig and Decker, 2001 ), may be due to effects of 2Ј,3Ј-cAMP, 2Ј-AMP, and 3Ј-AMP. In this regard, rapamycin is commonly used for renal transplant patients because of its lower renal toxicity relative to that of other immunosuppressants, and inhibition of proliferation of PGVSMCs and GMCs could be involved in this beneficial action. Other: Jackson acquired funding for the research. 
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